STOCK TITAN

Camp4 Therapeutics (CAMP) director granted options on 28,000 shares at $4.34

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Camp4 Therapeutics director and 10% owner Andrew J. Schwab reported receiving a grant of stock options representing 28,000 shares of common stock. The options have an exercise price of $4.34 per share and expire on June 9, 2036. According to the footnote, all shares underlying the option vest on the earlier of the first anniversary of the grant date or the issuer's next annual stockholder meeting, contingent on continued service. After this grant, Schwab holds 28,000 options directly.

Positive

  • None.

Negative

  • None.
Insider Schwab Andrew J.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 28,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 28,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 28,000 options Stock Option (Right to Buy) grant to Andrew J. Schwab
Exercise price $4.34 per share Conversion or exercise price of granted options
Expiration date June 9, 2036 Option expiration for Schwab’s 28,000 options
Underlying shares 28,000 shares Common Stock underlying the option grant
Post-grant derivative holdings 28,000 options Total options held following the reported transaction
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "4.3400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-09T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"The shares underlying the option vest in their entirety on the earlier of the first anniversary"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schwab Andrew J.

(Last)(First)(Middle)
C/O CAMP4 THERAPEUTICS CORPORATION
ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)
CAMBRIDGE MASSACHUSETTS 02139

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$4.3406/10/2026A28,000 (1)06/09/2036Common Stock28,000$028,000D
Explanation of Responses:
1. The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date.
Remarks:
/s/ Josh Mandel-Brehm, as Attorney-in-Fact06/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Camp4 Therapeutics (CAMP) report for Andrew J. Schwab?

Camp4 Therapeutics reported that director and 10% owner Andrew J. Schwab received a grant of stock options for 28,000 shares of common stock. These options were awarded at an exercise price of $4.34 per share and are held directly by him.

What are the key terms of Andrew J. Schwab’s Camp4 Therapeutics stock option grant?

Andrew J. Schwab was granted options covering 28,000 Camp4 Therapeutics common shares at a $4.34 exercise price. The options expire on June 9, 2036, giving him the right to buy shares at that price until the expiration date.

When do Andrew J. Schwab’s Camp4 Therapeutics stock options vest?

All shares underlying the option vest in full on the earlier of the first anniversary of the grant date or Camp4 Therapeutics’ next annual stockholder meeting. Vesting is conditioned on Schwab’s continued service to the company through the applicable vesting date.

How many Camp4 Therapeutics options does Andrew J. Schwab hold after this transaction?

Following this grant, Andrew J. Schwab holds 28,000 stock options in Camp4 Therapeutics. The Form 4 shows this as his total derivative holdings related to this specific award, with the options exercisable into an equal number of common shares once vested.

Is Andrew J. Schwab’s Camp4 Therapeutics option grant a market purchase or a compensation award?

The transaction is classified as a grant or award acquisition, not an open-market purchase. Schwab did not pay for the options at grant; instead, he received them as compensation with a $4.34 per share exercise price payable upon future exercise.